Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer
Status:
Unknown status
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Despite primary surgical management of muscle invasive bladder cancer (MIBC) with radical
cystectomy and pelvic lymphnode dissection, up to 50% of patients will eventually develop
tumours at distant sites, owing to pre-existing disseminated occult micrometastases. The
first line treatment for relapse or metastatic MIBC is gemcitabine and cisplatin. After the
failure of first line treatment, second line chemotherapy drugs can be chosen from
doxorubicin, docetaxel, pemetrexed, etc. This non-randomized, prospective study aims to
explore the efficacy and safety of PEGylated liposomal doxorubicin and PD-1 in second line
treatment of MIBC.